T Cell Receptor (Biomedical Science) Equipment
-
Manufactured by Oxford Vacmedix UK Limitedbased in UNITED KINGDOM
In the image below the Recombinant Overlapping Peptide is the “Antigen” being presented to the T Cell Receptor (TCR). This then triggers the growth of T Cells that will recognise the same marker on cancer cells leading to their destruction. ...
-
Manufactured by Immatics N.V.based in GERMANY
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel biologics allows any T ...
-
by Cellurisbased in BRAZIL
The chimeric T cell antigen receptor therapy, also known as CAR-T, is an immunotherapy that is innovating the treatment of hematological and solid tumors. This new technology is considered less aggressive than conventional treatments, since it focuses only on cancer cells, not attacking healthy ...
-
based in USA
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and ...
-
Manufactured by Celularity Inc.based in USA
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
-
Manufactured by TC BioPharmbased in UNITED KINGDOM
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous gamma delta T cell receptor (TCR), and combines it with chimeric antigen receptors. ...
-
based in USA
Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site Phase 1/2 clinical trial as an autologous monotherapy bridge-to-transplant for ...
-
Manufactured by Regeneron Pharmaceuticals Inc.based in USA
elociT™ is our unique mouse technology for producing fully human therapeutic T-cell receptors (TCR) against tumor and viral antigens. Regeneron uses this technology as part of its efforts to discover and develop novel immuno-oncology therapeutic candidates, including combination approaches and to assist our collaborators in producing ...
-
Manufactured by Immudex ApSbased in DENMARK
dCODE Dextramer technology enables the analysis of antigen-specific T cells by NGS or single-cell multi-omics. dCODE Dextramer adds a unique DNA barcode to the MHC Dextramer® reagent to detect antigen-specific T cells by NGS or single-cell multi-omics. High-avidity binding to ...
-
Manufactured by Gritstone Biobased in USA
We are leveraging EDGE to define targets for T-cell receptor (TCR) directed cell therapies. These additional targets that were identified and validated by Gritstone EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using ...
-
Manufactured by ProImmune Ltd.based in UNITED KINGDOM
or solution phase immunoassays for measuring interactions of predefined MHC Class II-peptide complexes with ligands such as monoclonal antibodies, recombinant T cell receptors, or other binding scaffolds, e.g. for use in screening of novel antigen-specific CAR T cell antigen ...
-
Manufactured by ProImmune Ltd.based in UNITED KINGDOM
Human MR1 Tetramers detect MAIT cells with human MR1 tetramers. ProImmune is the leading commercial source worldwide for fluorescently labeled human MR1 tetramers. MR1 complexes bind to T cell receptors on mucosal-associated invariant T (MAIT) cells. MAIT cells have a particular ...
-
based in USA
as the final step in the urea cycle. L-arginine is a necessary metabolite for T cell receptor signaling and T cell proliferation. Arginase is induced by inflammation. In cancer, MDSCs within the tumor microenvironment (TME) produce arginase-1 resulting in low levels of available L-arginine within the TME ...
-
Manufactured by 10x Genomicsbased in USA
Multiomic profiling of immune diversity, cell by cell. Chromium Single Cell Immune Profiling provides a multiomic solution to your immunology questions. Analyze full-length, paired B-cell or T-cell receptors, surface protein expression, antigen specificity, and gene expression, ...
-
Manufactured by Singleron Biotechnologies GmbHbased in GERMANY
GEXSCOPE Single Cell V(D)J Kit enables simultaneous detection of T-cell or B-cell receptor gene expression, together with whole transcriptome expression at single-cell ...
-
Manufactured by ProImmune Ltd.based in UNITED KINGDOM
CD1d Tetramers the world’s leading product for tracking NKT cells. Detect NKT Cells with CD1d Tetramers: ProImmune is the leading commercial source worldwide for fluorescently labeled human and mouse CD1d tetramers. CD1d-lipid complexes bind to T cell receptors of NKT cells of a particular ...
-
based in USA
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed ...
-
Manufactured by Elpisciencebased in CHINA
ES101 is a first-in-class tetravalent bispecific antibody targeting 4-1BB and PD-L1. It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune checkpoint target. 4-1BB targeting antibodies being developed by multinational companies have ...
-
Manufactured by Aptevo Therapeuticsbased in USA
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several hematological malignancies, ...
-
Manufactured by OSE Immunotherapeuticsbased in FRANCE
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you